Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6327-6340

  Speers, Corey ^a   Tsimelzon, Anna ^a   Sexton, Krystal ^a   Herrick, Ashley M ^a   Gutierrez, Carolina ^a   Culhane, Aedin ^b   Quackenbush, John ^b   Hilsenbeck, Susan ^a   Chang, Jenny ^a   Brown, Powel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; S6 KINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE REGULATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION;

EID: 70350235064     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1107     Document Type: Article

References (46)

1. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-369 (Pubitemid 36957839)
2. Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23:1169-1177 (Pubitemid 46202273)
3. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
4. van't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 2003;5:57-58
5. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536
6. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874 (Pubitemid 32878711)
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423 (Pubitemid 36842560)
8. Carey LA, Perou CM, Livasy CAu, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502 (Pubitemid 43854964)
9. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007;8:229-239 (Pubitemid 47524868)
10. Tan AR, Swain SM. Adjuvant chemotherapy for breast cancer: an update. Semin Oncol 2001;28:359-376 (Pubitemid 32762081)
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676
12. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007;7:153.
13. Dowell JE, Minna JD. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nat Clin Pract Oncol 2006;3:170-171
14. Herbst RS, Fukuoka M, Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-965 (Pubitemid 39626219)
15. Minna JD, Dowell J. Erlotinib hydrochloride. Nat Rev Drug Discov 2005;Suppl:S14-5.
16. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313. (Pubitemid 37361688)
17. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-553 (Pubitemid 36125831)
18. Tham YL, Gomez LF, Mohsin S, et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 2005;94:279-284 (Pubitemid 41677633)
19. Cleator S, Tsimelzon A, Ashworth A, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006;95:229-233
20. Mohsin SK, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-2468
21. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-36 (Pubitemid 32095858)
22. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002;62:3244-3250 (Pubitemid 34602420)
23. Zhang B, Schmoyer D, Kirov S, Snoddy J. GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 2004;5:16. (Pubitemid 38751319)
24. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol 2005;18:1368-1373
25. WangY, Klijn JG, ZhangY, et al. Gene-expression profiles to predict distant metastasis of lymphnode- negative primary breast cancer. Lancet 2005;365:671-679
26. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-1934 (Pubitemid 35425239)
27. Chan EY, Kir S, Tooze SA. siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy. J Biol Chem 2007;282:25464-25474 (Pubitemid 47372826)
28. Draviam VM, Stegmeier F, Nalepa G, et al. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol 2007;9:556-564 (Pubitemid 46696537)
29. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-13555 (Pubitemid 41420886)
30. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-4244 (Pubitemid 46630780)
31. Yu K, Ganesan K, Miller LD, Tan P. A modular analysis of breast cancer reveals a novel lowgrade molecular signature in estrogen receptorpositive tumors. Clin Cancer Res 2006;12:3288-3296 (Pubitemid 43910871)
32. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-132 (Pubitemid 43202662)
33. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541 (Pubitemid 44854748)
34. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-10301 (Pubitemid 44799747)
35. Ginestier C, Cervera N, Finetti P, et al. Prognosis and gene expression profiling of 20q13- amplified breast cancers. Clin Cancer Res 2006;12:4533-4544 (Pubitemid 44297802)
36. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-524
37. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357 (Pubitemid 43128862)
38. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527 (Pubitemid 44854747)
39. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157. (Pubitemid 351891480)
40. Amini RM, Aaltonen K, Nevanlinna H, et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 2007;7:165. (Pubitemid 350054212)
41. Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in African American and white women. Breast Cancer Res Treat 2001;68:33-43. (Pubitemid 32928269)
42. Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004;100:2533-2542
43. Padmanabhan S, Ravella S, Curiel T, Giles F. Current status of therapy for chronic myeloid leukemia: a review of drug development. Future Oncol 2008;4:359-377 (Pubitemid 351984088)
44. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9189 (Pubitemid 41507982)
45. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-326
46. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-10398 (Pubitemid 37071889)